Skip to main content
Marinomed Biotech AG logo

Marinomed Biotech AG — Investor Relations & Filings

Ticker · MARI ISIN · ATMARINOMED6 LEI · 529900GN3B1EN80XF405 VI Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2025-10-06 Regulatory Filings
Country AT Austria
Listing VI MARI

About Marinomed Biotech AG

https://www.marinomed.com/en

Marinomed Biotech AG is a biopharmaceutical company that develops medicinal products and medical devices for viral infectious diseases and immunological disorders. The company's innovation is driven by proprietary, patent-protected technology platforms. The Marinosolv platform enhances the solubility and bioavailability of poorly soluble compounds, enabling the development of treatments for immunological conditions such as allergies, asthma, and inflammatory diseases. The virology platform is the basis for therapies targeting viral respiratory infections. Marinomed maintains a development pipeline, has globally marketed therapeutics, and offers its technology through partnerships and services via its Solv4U unit.

Recent filings

Filing Released Lang Actions
EQS-Adhoc: Marinomed Biotech AG begins reviewing strategic options for the Marinosolv platform
Regulatory Filings Classification · 1% confidence The document is an 'Ad hoc announcement' regarding a strategic decision by Marinomed Biotech AG to review options for its Marinosolv platform. It is filed under Article 17 of the EU Market Abuse Regulation (MAR), which governs the disclosure of inside information. Since this is a regulatory disclosure of material corporate information that does not fit into specific categories like earnings, dividends, or board changes, it is classified as a Regulatory Filing (RNS).
2025-10-06 English
EQS-Adhoc: Marinomed Biotech AG startet Prüfung strategischer Optionen für die Marinosolv- Plattform
M&A Activity Classification · 1% confidence The document is an 'Ad-hoc' announcement (insider information) under Article 17 of the EU Market Abuse Regulation (MAR). It details a strategic decision by the board of Marinomed Biotech AG to evaluate options for its Marinosolv platform. Since this is a regulatory disclosure of material corporate information that does not fit into specific categories like earnings, dividends, or share transactions, it is classified as a Regulatory Filing (RNS).
2025-10-06 German
Marinomed Biotech AG begins reviewing strategic options for the Marinosolv platform
Regulatory Filings Classification · 1% confidence The document is an 'Ad-hoc announcement' regarding a strategic decision by Marinomed Biotech AG to review options for its Marinosolv platform. It is classified as a regulatory filing (RNS) because it is an official disclosure of inside information under Article 17 of the EU Market Abuse Regulation (MAR), transmitted via a news service (EQS Group). It does not fit into specific categories like M&A (as it is a review of options, not a definitive merger/takeover) or Earnings Release, making RNS the appropriate fallback for this type of regulatory disclosure.
2025-10-06 English
Marinomed Biotech AG announces results for the first half year of 2025
Earnings Release Classification · 1% confidence The document is a press release announcing the financial results for the first half of 2025 for Marinomed Biotech AG. It provides key financial highlights such as revenue, EBIT, and cash flow, along with management commentary. It is not a full interim report (which would be a comprehensive financial document) but rather an initial announcement of these results, fitting the definition of an Earnings Release (ER). H1 2025
2025-09-17 English
EQS-AFR: Marinomed Biotech AG: Release of a Financial report
Interim / Quarterly Report Classification · 1% confidence The document is titled '2025 Half-Year Financial Report' and contains comprehensive sections including a management report, business performance analysis, financial statements (statement of financial position, statement of profit or loss), and notes. It covers a period shorter than a full fiscal year (first half of 2025). It is not an announcement of a report, but the report itself, containing substantive financial data and analysis, which fits the definition of an Interim/Quarterly Report. H1 2025
2025-09-17 English
EQS-AFR: Marinomed Biotech AG: Bekanntmachung über die Veröffentlichung eines Finanzberichtes
Interim / Quarterly Report Classification · 1% confidence The document is titled '2025 Halbjahresfinanzbericht' (2025 Half-Year Financial Report) and contains comprehensive sections including a management report (Lagebericht), financial statements (Bilanz, Gewinn- und Verlustrechnung), and an audit review report (Bericht über die prüferische Durchsicht des Halbjahresabschlusses). It covers the financial performance for the first half of 2025, fitting the definition of an Interim/Quarterly Report. H1 2025
2025-09-17 German

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.